Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O3GF
|
||||
| Former ID |
DIB018225
|
||||
| Drug Name |
[3H]8-OH-DPAT
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H25NO
|
||||
| InChI |
InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-9-8-13-6-5-7-16(18)15(13)12-14/h5-7,14,18H,3-4,8-12H2,1-2H3
|
||||
| InChIKey |
ASXGJMSKWNBENU-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
4548205, 7978612, 8151037, 14798544, 24263030, 24439565, 26751756, 47217012, 47515552, 47662525, 47810997, 48334740, 49689465, 49689466, 49996002, 50104448, 50104716, 53787713, 57320820, 76860501, 85208931, 85787801, 90341547, 103167491, 103806993, 103857988, 104297104, 117429498, 117617246, 124749825, 124880271, 124880272, 125702543, 125822395, 127454624, 135014291, 135649864, 135651130, 137005647, 140448617, 162914574, 163426000, 163882658, 179236036, 179425877, 184561482, 204360699, 223818122, 226812125, 241138490
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1B receptor | Target Info | Agonist | [2] | |
| 5-hydroxytryptamine 1D receptor | Target Info | Agonist | [2] | ||
| 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [3] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 31). | ||||
| REF 2 | Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53. | ||||
| REF 3 | Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.